Today: 21 May 2026
Ondas Holdings (ONDS) stock jumps on rebrand, Florida HQ move — what traders watch next
5 January 2026
2 mins read

Ondas Holdings (ONDS) stock jumps on rebrand, Florida HQ move — what traders watch next

NEW YORK, Jan 4, 2026, 18:51 ET — Market closed

  • Ondas shares ended Friday up nearly 13% at $11.02 on heavy volume.
  • The company said it plans to rename itself Ondas Inc. and set West Palm Beach, Florida as its corporate headquarters.
  • Investors are watching a Jan. 5 share issuance tied to a securities exchange and a Jan. 15 debt maturity at a subsidiary.

Ondas Holdings Inc shares rose nearly 13% on Friday, closing at $11.02. The Nasdaq-listed drone and private wireless firm drew fresh attention after detailing a corporate rebrand and a headquarters relocation.

The changes matter because Ondas has been trying to reposition itself as an integrated defense, security and industrial technology operator, rather than a loose collection of assets. A name change is cosmetic, but it can help reset the narrative when a company is courting bigger customers and capital.

Timing also matters. Investor interest has been strong in small-cap autonomy names tied to military procurement and counter-drone systems, as demand rises for “counter-UAS” (counter-unmanned aircraft systems), industry shorthand for anti-drone technology. Ondas said on Dec. 31 it had received about $10 million in new purchase orders across its autonomous systems portfolio. Ondas Holdings Inc.

In a Jan. 2 statement, Ondas said it expects the name change to become effective during the first quarter of 2026 and that the move should not disrupt customer programs. Chairman and CEO Eric Brock said the new name “will better align our corporate identity” with the operating platform the company has built. Ondas Holdings Inc.

A separate filing showed Ondas Networks, a subsidiary, amended the maturity date of several convertible notes — debt that can be exchanged for shares — to Jan. 15, 2026. The filing described the change as a maturity extension via a letter agreement with noteholders.

In another filing, Ondas said some note and warrant holders deferred a securities exchange until Jan. 5, when about 2.39 million Ondas shares are set to be issued. The company also said it expected to record a one-time, non-cash charge estimated at about $56.6 million in the quarter ended Dec. 31, 2025 tied to that exchange.

A Form 144 — the notice insiders submit when they plan to sell shares under SEC Rule 144 — showed director Ron Stern planned to sell up to 100,000 shares, listing Morgan Stanley Smith Barney as broker. The filing put shares outstanding at about 368.5 million.

An initial ownership filing showed newly appointed chief operating officer, general counsel and corporate secretary Robert Patrick Huston held 100,000 restricted stock units and 100,000 stock options. Restricted stock units are equity awards that vest over time; the filing said Huston’s RSUs begin vesting in quarterly installments starting Feb. 4.

From a chart perspective, the stock finished Friday near its 52-week high of $11.70, with Friday’s intraday low around $9.92 marking a near-term reference point for support. Ondas has traded as low as $0.57 in the past 52 weeks, underscoring how quickly sentiment has shifted in the name.

The week ahead brings macro risk back into view. ISM’s calendar shows its manufacturing PMI report due Jan. 5 and its services PMI due Jan. 7, while the U.S. Labor Department’s schedule lists the December employment report for Jan. 9 — releases that often move rate expectations and small-cap risk appetite. Ondas’ investor relations calendar shows no upcoming events scheduled.

But the rally leaves little room for surprises. Any sign of financing strain ahead of the Jan. 15 note maturity, or extra selling pressure around new share issuance and insider-sale notices, could undercut the momentum.

The next tests are the expected issuance of about 2.39 million shares on Jan. 5 and the Networks notes coming due on Jan. 15.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
CrowdStrike stock fell 3% Friday — what to watch before markets reopen
Previous Story

CrowdStrike stock fell 3% Friday — what to watch before markets reopen

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop
Next Story

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop

Go toTop